Premium
Liver Transplantation After Ex Vivo Normothermic Machine Preservation: A Phase 1 (First‐in‐Man) Clinical Trial
Author(s) -
Ravikumar R.,
Jassem W.,
Mergental H.,
Heaton N.,
Mirza D.,
Perera M. T. P. R.,
Quaglia A.,
Holroyd D.,
Vogel T.,
Coussios C. C.,
Friend P. J.
Publication year - 2016
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.13708
Subject(s) - machine perfusion , medicine , transplantation , liver transplantation , ex vivo , cold storage , perfusion , viaspan , surgery , ischemia , cold ischemia , urology , in vivo , reperfusion injury , biology , microbiology and biotechnology , horticulture
The number of donor organs suitable for liver transplantation is restricted by cold preservation and ischemia–reperfusion injury. We present the first patients transplanted using a normothermic machine perfusion (NMP) device that transports and stores an organ in a fully functioning state at 37°C. In this Phase 1 trial, organs were retrieved using standard techniques, attached to the perfusion device at the donor hospital, and transported to the implanting center in a functioning state. NMP livers were matched 1:2 to cold‐stored livers. Twenty patients underwent liver transplantation after NMP. Median NMP time was 9.3 (3.5–18.5) h versus median cold ischaemia time of 8.9 (4.2–11.4) h. Thirty‐day graft survival was similar (100% NMP vs. 97.5% control, p = 1.00). Median peak aspartate aminotransferase in the first 7 days was significantly lower in the NMP group (417 IU [84–4681]) versus (902 IU [218–8786], p = 0.03). This first report of liver transplantation using NMP‐preserved livers demonstrates the safety and feasibility of using this technology from retrieval to transplantation, including transportation. NMP may be valuable in increasing the number of donor livers and improving the function of transplantable organs.